Uchida S, Shimada Y, Watanabe G, Li Z G, Hong T, Miyake M, Imamura M
Department of Surgery and Surgical Basic Science, Graduate School of Medicine, Kyoto University, Japan.
Br J Cancer. 1999 Mar;79(7-8):1168-73. doi: 10.1038/sj.bjc.6690186.
Although the mechanisms of action of the transmembrane superfamilies, motility-related protein-1 (MRP-1/CD9) and KAI1/CD82, are not well known, they are reported to suppress the metastasis of several kinds of cancers. The suppression of cell motility by MRP-1/CD9 may cause suppression of the metastasis. As we could not find any reports concerning the expression of MRP-1/CD9 and KAI1/CD82 in oesophageal cancers we investigated their expression in oesophageal specimens. We conducted immunohistochemical staining for MRP1/CD9 against 108 cases of oesophageal squamous cell carcinoma using anti-MRP-1/CD9 monoclonal antibody M31-15, and for KAI1/CD82 against 104 cases using anti-KAI1/CD82 monoclonal antibody C33. To investigate the gradual expression of MRP-1/CD9 and KAI1/CD82, 24 oesophageal dysplasias were immunohistochemically stained using the same method and then investigated. The expression of both MRP-1/CD9 and KAI1/CD82 were positive on the cell membranes of normal oesophageal epithelial cells, but reduced or negative in the cancer cells. Reduced MRP-1/CD9 expressions significantly correlated to tumour depth (P = 0.0009). We found a significantly greater number of reduced or negative expression of MRP-1/CD9 and KAI1/CD82 in lymph node metastatic cases (P = 0.0003 and P= 0.0129, respectively), but not in distant metastatic cases. The 5-year survival rate of MRP-1/CD9-negative and reduced patients was significantly worse than those of positive patients (n = 108, curative cases, RO). Few cases remained KAI1/CD82-positive (9.6%; 10/104) in oesophageal cancer. Twenty (83.3%) and twenty-two (91.7%) cases out of 24 dysplasias were defined as KAI1/CD82-positive and MRP1/CD9-positive, respectively. The decrease in MRP-1/CD9 and KAI1/CD82 expression may facilitate lymph node metastasis in oesophageal squamous cell carcinomas. Knowing the status of the expression of MRP-1/CD9 appears helpful in predicting the prognosis for each patient.
尽管跨膜超家族成员、与运动相关蛋白-1(MRP-1/CD9)和KAI1/CD82的作用机制尚不清楚,但据报道它们可抑制多种癌症的转移。MRP-1/CD9对细胞运动性的抑制可能导致转移受到抑制。由于我们未找到关于MRP-1/CD9和KAI1/CD82在食管癌中表达情况的任何报道,因此我们研究了它们在食管标本中的表达。我们使用抗MRP-1/CD9单克隆抗体M31-15对108例食管鳞状细胞癌进行MRP1/CD9的免疫组织化学染色,使用抗KAI1/CD82单克隆抗体C33对104例进行KAI1/CD82的免疫组织化学染色。为了研究MRP-1/CD9和KAI1/CD82的表达变化,对24例食管发育异常组织采用相同方法进行免疫组织化学染色并进行研究。MRP-1/CD9和KAI1/CD82在正常食管上皮细胞膜上的表达均为阳性,但在癌细胞中表达降低或为阴性。MRP-1/CD9表达降低与肿瘤深度显著相关(P = 0.0009)。我们发现,在有淋巴结转移的病例中,MRP-1/CD9和KAI1/CD82表达降低或为阴性的病例数显著更多(分别为P = 0.0003和P = 0.0129),但在远处转移病例中并非如此。MRP-1/CD9表达为阴性和降低的患者的5年生存率显著低于阳性患者(n = 108,根治性病例,RO)。食管癌中KAI1/CD82仍为阳性的病例很少(9.6%;10/104)。在24例发育异常组织中,分别有20例(83.3%)和22例(91.7%)被定义为KAI1/CD82阳性和MRP1/CD9阳性。MRP-1/CD9和KAI1/CD82表达的降低可能促进食管鳞状细胞癌的淋巴结转移。了解MRP-1/CD9的表达状态似乎有助于预测每位患者的预后。